Clinical Trial Update: A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies [Phase 1]

View source ↗

Summary

This update states that the first-in-human Phase I study of ESG206 in B-cell lymphoid malignancies has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoid Malignancies

Drugs mentioned

• ESG206

Snippet

Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Conditions: B-cell Lymphoid Malignancies | Phase 1 | Status: WITHDRAWN